Cancer patients who responded to balstilimab can now continue treatment through expanded access
Disease control
AVAILABLE
This expanded access study offers balstilimab alone or combined with zalifrelimab to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who qualify. Participants must have completed the earli…
Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC